Ukko is a technology company.
Ukko has raised $40.0M across 1 funding round.
Ukko has raised $40.0M in total across 1 funding round.
Ukko has raised $40.0M in total across 1 funding round.
Ukko's investors include Cantos Ventures, Kindred Ventures, LGF, Offline Ventures, Salesforce Ventures, Tiger Global Management, Sam Altman.
Ukko is a biotechnology company specializing in developing innovative therapeutics and food solutions for food allergies and sensitivities using artificial intelligence (AI) and computational protein design. It serves millions of people affected by food allergies, particularly targeting life-threatening conditions such as peanut allergies and gluten-related disorders. Ukko’s platform designs modified allergens that retrain the immune system to tolerate specific food proteins without triggering allergic reactions. The company has demonstrated strong growth momentum, having raised $47.7 million in funding, including a $40 million round to advance clinical trials and product development[1][3][4].
Founded in 2016 in Tel Aviv, Israel, Ukko was co-founded by experts including Professor Yanay Ofran and Anat Binur, who bring deep knowledge in immunology and biotechnology. The idea emerged from the urgent need to address the rising global epidemic of food allergies through a novel, science-driven approach that combines AI, protein engineering, and immunology. Early pivotal moments include securing significant funding and advancing toward clinical validation of their peanut allergy therapy and gluten-safe products for celiac patients[1][3][4].
Ukko rides the convergence of biotechnology, artificial intelligence, and personalized medicine trends, addressing a growing global health challenge—food allergies—that have significant social and economic impacts. The timing is critical as food allergies rise worldwide, and there is increasing demand for safer food products and effective therapies. Market forces such as heightened consumer awareness, regulatory interest, and advances in synthetic biology and AI-driven drug design favor Ukko’s innovative approach. By bridging food technology and therapeutics, Ukko influences both the biotech ecosystem and the food industry’s future, potentially redefining how food and medicine intersect[1][2][3][4].
Looking ahead, Ukko is positioned to expand its pipeline beyond peanut and gluten allergens to address other major food allergies, leveraging its AI platform for rapid innovation. Trends such as personalized nutrition, AI in drug discovery, and growing investment in food tech will shape its trajectory. Ukko’s influence is likely to grow as it moves toward commercializing therapies and allergen-safe food products, potentially transforming the lives of millions worldwide and setting new standards in allergy treatment and food safety. Its mission to eliminate food allergies aligns with broader health and sustainability goals, making it a key player to watch in biotech and food innovation[3][4].
Ukko has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series B in January 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2021 | $40.0M Series B | Cantos Ventures, Kindred Ventures, LGF, Offline Ventures, Salesforce Ventures, Tiger Global Management, Sam Altman |